Introduction {#s1}
============

Type XI collagen along with type II collagen, forms the heterotypic fibrillar collagen fibrils found in cartilage and vitreous. It is a heterotrimer, encoded by three genes *COL11A1* (MIM 120280), *COL11A2* (MIM 120290) and *COL2A1* (MIM 120140),[@R1; @R2; @R3; @R4; @R5; @R6; @R7] the latter also encodes the homotrimer type II collagen that constitutes the major component of these collagen fibrils. Although type XI collagen is a quantitatively minor component of the fibrils it has an important role in regulating fibrillogenesis.[@R8] Mutations of all three genes can result in different types of Stickler syndrome (MIM 108300, 604841, 184840),[@R9; @R10; @R11] which is usually an autosomal dominant disorder with variable phenotype that includes myopia, retinal detachment, premature osteoarthritis, hearing loss, facial dysmorphism and midline clefting that can manifest as Pierre Robin sequence, or an isolated cleft palate.[@R12] The *COL11A2* gene is not expressed in the eye and mutations in that gene do not result in an eye phenotype.[@R13] A recessive form of Stickler syndrome (MIM 614134, 614284)[@R14] [@R15] has been reported in association with null alleles of type IX collagen genes (*COL9A1* MIM 120210 and *COL9A2* MIM 120260). Type IX collagen connects heterotypic type II/XI collagen fibrils to other components of the extracellular matrix.[@R16] [@R17]

A recent systematic review of published information on hearing loss in Stickler syndrome[@R18] concluded that more than half of all patients have some form of hearing loss, but that this may vary between the different types. Hearing loss is usually mild to moderate, however when associated with COL11A1 and COL11A2 it is more common, more severe and presents at a younger age than for COL2A1. In the recessive forms, due to mutations in type IX collagen, the hearing loss is variable and has been described as mild to severe.[@R14] [@R15]

The recessive disorder fibrochondrogenesis (MIM 228520), which is usually lethal, has also been shown to be due to mutations in *COL11A1*.[@R19] [@R20] In that disorder the mutations are either a combination of null alleles and missense mutations or biallelic null alleles. The carrier parents showed only mild clinical features such as myopia or hearing loss and were not considered to have Stickler syndrome.

*COL11A1*, *COL11A2* and *COL2A1* are all subject to alternative splicing,[@R21] [@R22] where inclusion or exclusion of exons encoding the N-propeptide region of the molecules results in isoforms that can vary in their interaction with other components of the extracellular matrix[@R23] and growth factors such as TGFβ1 and BMP-2.[@R24] As previously demonstrated, mutations in the alternatively spliced exon 2 of *COL2A1* result in a non-systemic (or predominantly ocular) form of type 1 Stickler syndrome[@R25] (MIM 609508). Here we demonstrate that mutations, in two families, affecting the alternatively spliced exon 9 (also referred to as exon 8 or variable region 2)[@R26] [@R27] of *COL11A1* which is not expressed in cartilage,[@R28] are modified by the natural alternative splicing that occurs in this gene. Both cases have a second mutation, but the combination of the two results in a recessive form of type 2 Stickler syndrome with profound hearing loss, rather than the more severe fibrochondrogenesis. In addition, we describe a third family with recessive type 2 Stickler syndrome that have a silent mutation which is variably spliced and able to express at least some normal α1(XI) collagen.

Materials and methods {#s2}
=====================

Three families referred to the national Stickler syndrome diagnostic service for England were assessed clinically and with informed written consent, subsequently screened for mutations in *COL11A1*. The study was approved by the local research ethics committee.

Gene analysis {#s2a}
-------------

The *COL11A1* gene was analysed by amplification and sequencing of all exons as previously described.[@R29] In addition, possible regions of gene deletion/duplication were examined by multiplex ligation-dependent probe amplification using commercially available probes (MRC-Holland, Amsterdam, the Netherlands). The cDNA numbering is derived from the *COL11A1* transcript NM_001854.3. The exons are numbered 1--68 as described in the reference sequences (NM_001854.3, NM_080692.2 and NM_080693.3), where exons 6, 7 and 9 are alternatively spliced, rather than numbered as exons 1--67 as in Annunen *et al*[@R27] Transcript NM_001854.3 contains exons 6 and 9 (also referred to as exon 6A and 8, respectively) but not exon 7 (also referred to as exon 6B).

Mutation analysis {#s2b}
-----------------

The effect of sequence variants on pre-mRNA processing was assessed in silico and functionally. Functional studies were performed using either minigenes as splicing reporters or cultured cells obtained from a heterozygous carrier. The minigene system USR13[@R30] consisted of a cassette of four exons (43--46) from the *COL2A1* gene into which a test exon could be inserted to obtain normal and variant hybrid minigene constructs. These could then be expressed in cultured mammalian cells. Cultured dermal fibroblasts obtained from patients were incubated with and without emetine, an inhibitor of nonsense mediated decay (NMD). RNA prepared from either transfected or patients' cells was analysed by reverse transcription PCR (RT-PCR) as previously described.[@R30]

Sequence variations were analysed in silico, using Alamut V.2.0 (Interactive Biosoftware, Rouen, France), a software package that uses four different programmes to predict the effect of variants on pre-mRNA splicing (as previously described)[@R30] and three programmes to analyse the effect of amino acid changes on protein function. These are PolyPhen-2, sorting intolerant from tolerant (SIFT) and align Grantham variation Grantham deviation (GVGD), which are also freely available as separate stand alone utilities, (<http://genetics.bwh.harvard.edu/pph2/>, <http://sift.jcvi.org/>, <http://agvgd.iarc.fr/>).

Quantitative RT-PCR {#s2c}
-------------------

RNA isolated from cultured cells of the carrier for the c.2607A\>G, p.Ala869Ala was reverse transcribed with a gene specific primer and superscript II (Invitrogen, <http://www.invitrogen.com>). The relative amount of the G allele was compared with the expression of the A allele by quantitative PCR using primers located in exon 32 and 33 and fluorescently labelled cDNA probes specific for each allele. RNA from a normal individual was used as a positive control for the A allele and a negative control for the G allele. Each reaction was performed in triplicate and this was repeated three times. A chromo4 machine (BioRad, <http://www.bio-rad.com>) was used to measure the amount of fluorescence produced from each amplification reaction, and the Opticon-Monitor software (BioRad, <http://www.bio-rad.com>) was used to measure the relative difference in expression between the normal A and mutant G allele.

Results {#s3}
=======

In each family, two unique mutations/variants were found as illustrated in [figure 1](#JMEDGENET2012101499F1){ref-type="fig"} and online [supplementary figure S1](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2012-101499/-/DC1).

![Inheritance patterns of mutations. The pedigrees indicate the inheritance of each mutation in three different families. Solid squares/circles indicate individuals with type 2 Stickler syndrome. Vertical bars are carriers that had minor clinical signs associated with Stickler syndrome or a normal clinical appearance.](jmedgenet-2012-101499f01){#JMEDGENET2012101499F1}

Family 1 {#s3a}
--------

The proband had been born with a cleft palate and subsequently found to be profoundly deaf with no recordable response from the left ear up to 100 dB and only a barely recordable response at 250 Hz/100 dB for the right ear. She communicates as an adult with sign language. Despite being hypermetropic (+3.50DS right, +4.50DS left) ophthalmological assessment revealed a hypoplastic vitreous gel architecture,[@R29] without the membranous or beaded congenital vitreous anomaly. Assessment of her parents revealed insignificant, age-compatible sensorineural hearing loss for her mother (25 dB/4000 Hz) and mild to moderate sensorineural hearing loss in her father (40 dB/1000--4000 Hz). Both parents had unremarkable vitreous architecture, exhibiting only mild age related vitreous syneresis. The pedigree is illustrated in [figure 1](#JMEDGENET2012101499F1){ref-type="fig"}.

Mutations in exon 9 (c.1191delT, p.Asn398Metfs\*19) and exon 58 (c.4259G\>T, p.Gly1420Val) were found in the proband. Analysis of the parents' DNA showed that the proband had inherited one mutation from each parent. The c.1191delT mutation has been previously reported, but erroneously located in exon 6 instead of exon 9.[@R31] Because skipping of exon 9 would leave the message inframe and a functional collagen expressed, studies using RNA obtained from cultured dermal fibroblasts with the exon 9 mutation (c.1191delT) were used to assess whether any nonsense associated exon skipping resulted from this mutation. Cultured dermal fibroblasts which constitutively express the alternatively spliced exon 9 were treated with a nonsense mediated decay inhibitor. Amplification of cDNA ([figure 2](#JMEDGENET2012101499F2){ref-type="fig"}A), showed that the uninhibited cells produced a homozygous cDNA sequence which included exon 9, and since nonsense associated exon skipping would have resulted in a heterozygous sequence, this demonstrated that only the normal allele was expressed. Cells treated with the NMD inhibitor expressed both alleles, thereby confirming that the mutant allele would normally be naturally degraded by this cellular RNA quality surveillance system. However in tissues not expressing exon 9 the mutation would be naturally removed from the mature transcript. The p.Gly1420Val mutation disrupted the Gly-Xaa-Yaa amino acid repeat sequence of the collagen molecule, which is typical of pathogenic mutations in collagen molecules, and was predicted to be pathogenic by all three protein analysis tools in Alamut.

![Analysis of exon 9 mutations c.1191delT and c.991-24A\>G by RT-PCR. RNA from a cell line heterozygous for the c.1191delT mutation was analysed by RT-PCR and sequenced (A). cDNA from cells incubated with emetine to inhibit NMD (−NMD) had the frameshift mutation, whereas cDNA from uninhibited cells (+NMD) had a homozygous sequence from the normal allele only. *COL11A1* exon 9, including 682 bp of surrounding intron sequence, was amplified from genomic DNA containing the c.991-24A\>G mutation (B). This was cloned into the splicing reporter USR13, between *COL2A1* exons 44 and 45. Normal and mutant alleles were expressed in MIO-M1 cells, with the resulting RNA analysed by RT-PCR and sequencing (B). The variant cDNA had an additional 23 bp, which corresponded to the sequence from *COL11A1* IVS8 and a de novo acceptor splice site created by the mutation. Green=A, red=T, blue=C, black=G.](jmedgenet-2012-101499f02){#JMEDGENET2012101499F2}

Family 2 {#s3b}
--------

Two young boys, with severe and profound hearing loss, presented with parents who exhibited only mild clinical signs associated with Stickler syndrome, but were not considered to have the disorder. The proband was referred at age 20 months having been born with congenital high myopia (−7DS bilaterally), Pierre Robin sequence and profound hearing loss (90 dB), for which he had been treated with bilateral cochlear implants. His newborn brother (18 days old) also had Pierre Robin sequence and auditory brainstem assessment demonstrated no recordable responses at over 95 dB; typanometry was normal. Audiometry findings were confirmed on retesting and cochlear implants are planned. Their father had a high arched palate and mild, asymptomatic high tone hearing loss. The mother exhibited mild, asymptomatic hearing loss (35 dB/1000--2000 Hz); she also reported a history of hearing loss in her family. She had healthy compact vitreous gel architecture. The pedigree is illustrated in [figure 1](#JMEDGENET2012101499F1){ref-type="fig"}. Analysis of *COL11A1* identified a frameshift mutation c.1421dupC, p.Gly475Argfs\*9 in exon 13 and a sequence variant c.991-24A\>G in intron 8 which was absent from the dbSNP (single nucleotide polymorphism) variation database (<http://www.ncbi.nlm.nih.gov/snp>). In silico analysis of this variant predicted that it created an alternative exon 9 acceptor splice site. It was also analysed functionally using minigenes, by cloning the normal and variant alleles into the splicing reporter USR13. This vector has been successfully used to assess other non-AG-GT splice site mutations that result in exon skipping and dominant type 2 Stickler syndrome (see online [supplementary figure S2](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2012-101499/-/DC1)), including one (c.1845+5G\>A) known to result in exon skipping in cultured cells.[@R29] The normal and mutant minigenes produced a small amount of exon skipping, which reflected that this exon is alternatively spliced. However, the full length mutant cDNA appeared larger than the normal cDNA. This was confirmed by specifically amplifying and sequencing transcripts which included the 255 bp exon 9 ([figure 2](#JMEDGENET2012101499F2){ref-type="fig"}, see online [supplementary figure S2B](http://jmg.bmj.com/lookup/suppl/doi:10.1136/jmedgenet-2012-101499/-/DC1)). The mutant transcript contained an insertion of an additional 23 bp at the start of exon 9 which corresponded to the creation of an acceptor splice site by the mutation, as predicted by in silico analysis. It caused a shift in the reading frame and a downstream premature termination codon. Despite the normal acceptor splice site being present, it was not used in the minigene experiments, as the sequence obtained from the variant clone was homozygous ([figure 2](#JMEDGENET2012101499F2){ref-type="fig"}B). Because exon 9 is not expressed in all tissues (NM_080630.3, transcript variant C) this mutation, like the c.1191delT mutation, would be naturally removed from transcripts in those tissues and have no effect.

Family 3 {#s3c}
--------

The proband was a young girl ([figure 3](#JMEDGENET2012101499F3){ref-type="fig"}), born prematurely at 32 weeks and tube fed for 4 weeks, but without any evidence of a cleft palate. Hearing loss was diagnosed at 5 weeks of age, later being confirmed with pure tone audiometry which showed severe mixed conductive and sensorineural hearing loss from 250 Hz--8000 Hz with flat tympanometry. At 2 years of age concerns about visual development and a very pale fundal reflex led to referral for investigation of a possible retinal dystrophy. Refraction under cycloplegia revealed high myopia (−12:50DS right, −12:50DS left) and slit-lamp examination noted the type 2 beaded vitreous anomaly, associated with mutations in *COL11A1*.[@R29] Despite the high refractive error, the discs were of normal size and configuration. A clinical diagnosis of probable type 2 Stickler syndrome was made. Full field electroretinogram, pattern reversal visual evoke potential and flash visual evoke potential were normal. Both parents exhibited healthy compact vitreous gel architecture and no evidence of hearing loss on audiology testing. The proband exhibited clinical joint laxity, but with no evidence of dysplastic changes of the hips or pelvis visible on radiology. Analysis of *COL11A1* identified a silent variant c.2607A\>G, p.Ala869Ala and a missense alteration c.5398G\>T, p.Gly1800Cys. Both of these changes are novel and were absent from the dbSNP variation database (<http://www.ncbi.nlm.nih.gov/snp>). Analysis of the parents' DNA showed that the silent variant was inherited from the father and the missense change from the mother. Analysis in silico predicted that the silent DNA variant created a donor splice site within exon 33 and also a potential binding site for the splicing factor SRp55. Using RNA obtained from the father\'s cultured dermal fibroblasts, RT-PCR demonstrated three splice isoforms ([figure 4](#JMEDGENET2012101499F4){ref-type="fig"}). First, RNA from cells uninhibited for NMD had the normal and variant sequence, demonstrating that the variant allele could be spliced normally, although there appeared to be unequal peak heights in the sequence chromatogram ([figure 4](#JMEDGENET2012101499F4){ref-type="fig"}). Using RNA from cells where NMD was inhibited, the use of the variant sequence as a donor splice site was observed by sequencing in the reverse direction, confirming the in silico prediction. In addition to the variant creating a donor splice site in the exon, sequencing in the forward direction also identified insertion of 16 nucleotides between exons 32 and 33. An examination of intron 32 showed that the inserted sequence was present at c.2557--186 to −171, it was preceded by a cag sequence and followed by the sequence gtaagt, which matched consensus acceptor and donor splice sites, respectively. Therefore the inserted sequence represented a pseudoexon which was activated by the c.2607A\>G variant. Both of the misspliced transcripts resulted in frameshifts and premature termination of translation, reducing the level of expression from the mutant G allele. Quantitative RT-PCR indicated that the expression of the G allele was approximately 42 ± 3.5% of the normal A allele (data not shown), meaning that the misspliced transcripts represented around 58% of transcripts from the G allele.

![Facial photographs of a child with recessive type 2 Stickler syndrome. The child has c.2607A\>G, p.Ala869Ala and c.5398G\>T, p.Gly1800Cys mutations in *COL11A1*. The p.Gly1800Cys was inherited from her mother who is also shown.](jmedgenet-2012-101499f03){#JMEDGENET2012101499F3}

![RT-PCR analysis of the c.2607A\>G, p.Ala869Ala mutation. Cultured cells from a heterozygous carrier were incubated with (−NMD) or without (+NMD) emetine to inhibit nonsense mediated decay. NMD was also inhibited in a normal cell line as a control. RNA was analysed by RT-PCR and sequenced in the forward (A) and reverse (B) directions. Text sequence represents the sequence seen in uninhibited cells (upper) and the additional sequence obtained from inhibited cells (lower). In (A) an additional sequence was located between exons 32 and 33 (in bold type), which corresponded to a pseudoexon in intron 32. In the reverse direction, the mutant sequence (arrowed) was present in cDNA from uninhibited (+NMD) cells. When nonsense mediated decay was inhibited an additional transcript was seen which corresponded to the use of the GTGCAC sequence (in bold) as a donor splice site.](jmedgenet-2012-101499f04){#JMEDGENET2012101499F4}

The missense change inherited from the mother changed a conserved glycine to cysteine in the C-propeptide region of the molecule ([figure 5](#JMEDGENET2012101499F5){ref-type="fig"}). Disruption to the pattern of cysteines in the C-propeptide of collagen molecules has been found in various other collagenopathies[@R32] and in silico analysis predicted that the amino acid change was damaging.

![Multiple sequence alignment of the C-termini of the fibrillar collagens. Amino acids identical in at least seven of the nine protein sequences are in bold type. The position of the p.Gly1800Cys mutation is indicated.](jmedgenet-2012-101499f05){#JMEDGENET2012101499F5}

Discussion {#s4}
==========

Stickler syndrome is usually a dominant disorder due to mutations in the collagen genes *COL2A1*, *COL11A1* and *COL11A2*. Although there are rare recessive forms, these have all been reported in consanguineous families where the mutations have been homozygous.[@R14] [@R15] [@R31] [@R33] Here we report three non-consanguineous families with a novel recessive form of type 2 Stickler syndrome, without consanguinity to assist interpretation of the sequence variants detected. In all three, the phenotype is different from that documented with recessive type IX collagen mutations[@R14] [@R15] and is characterised by unusually severe/profound hearing loss. In two children this required cochlea implants, while an adult patient communicates by sign language.

The majority of mutations that result in dominant type 2 Stickler syndrome have been found to affect consensus splice sites in the *COL11A1* gene and result in exon skipping. Because of the nature of exons in collagen genes, which typically encode a complete set of Gly-Xaa-Yaa amino acid repeat sequences, such mutations result in shortened α1(XI) procollagens that exert a dominant negative effect upon normal gene products with which they coassemble. Other mutations alter obligate glycines that must occur at every third position in the 1014 residue collagen triple helical domain.

Further phenotypes associated with mutations in *COL11A1* are Marshall syndrome and fibrochondrogenesis. Marshall syndrome is a differential diagnosis to type 2 Stickler syndrome, it results mainly from exon skipping mutations of *COL11A1* and differs in the severity of facial features that may be present.[@R27] Fibrochondrogenesis was first characterised molecularly by Tompson *et al*,[@R19] who found heterozygous null alleles inherited along with a substitution of an obligate glycine on the second allele. Later Akawi *et al*[@R20] characterised two families who both had biallelic null mutations. Here we have demonstrated how, due to alternative splicing, which can be either natural or pathogenic in origin, similar null/missense or biallelic null mutations result in Stickler syndrome rather than fibrochondrogenesis ([table 1](#JMEDGENET2012101499TB1){ref-type="table"}).

###### 

Effect of recessive mutations in families 1, 2 and 3

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mutation                         Effect                                                                               Comment
  -------------------------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------
  Family 1                                                                                                              

   c.1191delT, p.Asn398Metfs\*19   Premature termination of translation and NMD                                         Only affects transcripts containing exon 9

   c.4259G\>T, p.Gly1420Val        Disrupts the collagen\                                                               Classical type of collagen mutation
                                   Gly-Xaa-Yaa helical domain                                                           

  Family 2                                                                                                              

   c.991-24A\>G                    Creates cryptic acceptor splice site, premature termination of translation and NMD   Only affects transcripts containing exon 9

   c.1421dupC, p.Gly475Argfs\*9    NMD                                                                                  Null allele

  Family 3                                                                                                              

   c.2607A\>G, p.Ala869Ala         Normal and Missplicing, premature termination of translation and NMD                 Reduces the level of expression from the mutant allele

   c.5398G\>T, p.Gly1800Cys        Disrupts pattern of C-propeptide cysteines                                           Known to be disruptive in other collagen C-propeptides.
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Exon 9/intron 8 mutations {#s4a}
-------------------------

The c.1191delT mutation seen in family 1 has been previously reported in a homozygous state,[@R31] emphasising the recessive nature of this mutation. However, Alzahrani *et al*[@R31] erroneously located the mutation in exon 6. As in family 1 the patient described by Alzahrani *et al*[@R31] had hearing loss, cleft palate but not myopia, although vitreoretinal degeneration was present in both. Alzahrani *et al* suggested that the resulting Stickler phenotype questioned whether fibrochondrogensis was simply a case of *COL11A1* deficiency, and failed to consider that in fact exon 9 is naturally alternatively spliced[@R26; @R27; @R28] and that only transcripts expressing this exon (NM_001854.3, NM_080692.2 transcript variants A and B) will be affected. Whereas transcript variant C (NM_080693.3) expressed in cartilage will not be altered. The examples of recessive Stickler syndrome that we describe here demonstrate that their premise is likely to be incorrect, and that the recessive Stickler syndrome phenotype is more probably due to the ability to synthesise normal α1(XI) collagen molecules because the mutations are removed by naturally occurring alternative splicing.

The expression of *COL11A1* exon 9 in rat long bones is similar to the expression of the long form of type II collagen, that contains the region encoded by exon 2 of *COL2A1*.[@R34] Both are present in immature chondrocytes but disappear as these cartilage precursors differentiate and mature. This would explain why the resulting phenotype in these individuals presented as Stickler syndrome rather than fibrochondrogenesis. As with the mechanism that removes mutations in exon 2 from *COL2A1* and results in a non-systemic form of Stickler syndrome,[@R25] so the natural alternative splicing of *COL11A1* exon 9 modifies the effect of the mutations, consequently the severity of abnormal skeletal development is reduced. However, this exon is expressed in Meckel\'s cartilage[@R26] which gives rise to the malleus and incus of the inner ear, in addition to the anterior ligament of the malleus tympanic plate,[@R35] which is likely to explain why there is a more severe hearing than skeletal phenotype in these patients.

Like the c.1191delT mutation the c.991-24A\>G mutation in intron 8, seen in family 2, will only affect tissues that express exon 9. Although not obviously pathogenic a combination of functional minigene analysis*,* in silico analysis, absence from the variation sequence databases and inheritance patterns, together indicate the pathogenic nature of this mutation. The family with the c.991-24A\>G mutation also had a frameshift c.1421dupC mutation, predicted to result in two null alleles, similar to the families described by Akawi *et al*,[@R20] except that here one (c.991-24A\>G) is modified by alternative splicing of exon 9, whereas those causing fibrochondrogenesis affect constitutive exons.

Glycine substitution {#s4b}
--------------------

As with the cases of fibrochondrogenesis described by Tompson *et al*,[@R19] one patient characterised here possesses similar null/missense mutations, but has Stickler syndrome instead. The missense mutation p.Gly1420Val was coinherited with a null allele due to a mutation (c.1191delT) in the alternatively spliced exon 9. The missense mutation was also present in the patient\'s mother who exhibited only age-related hearing loss and no other clinical signs usually associated with mutations of *COL11A1*. This may be surprising, however, in other fibrillar collagens the substitution of obligate glycines can result in a wide range of phenotypic severity from lethal to mild, with the genes for type I collagen and osteogenesis imperfecta being the most studied.[@R36] To date only eleven glycine substitutions have been described in *COL11A1*, and so the range of possible resulting phenotypic variation is currently unknown and difficult to predict from any particular missense mutation. The heterozygous carriers of similar glycine substitutions described by Tompson *et al*[@R19] were also not considered to have Stickler syndrome and presented with only mild phenotypes, such as myopia or hearing loss. It would therefore appear that as with the quantitatively major collagens such as type I and type II collagen, substitutions of an obligate glycine in α1(XI) collagen can result in a spectrum of phenotypes, some resulting in Stickler syndrome, while others may produce only subtle clinical features not recognised as that disorder. The report of recessive Marshall syndrome[@R37] in a consanguineous family with a homozygous glycine substitution in α1(XI) collagen supports this conclusion. In heterozygous cases of recessive type 2 Stickler syndrome there is a risk that a glycine substitution may be mistaken for dominant mutation, and the recessive nature of the change overlooked.

Silent mutation {#s4c}
---------------

As has previously been seen in COL2A1 and type 1 Stickler syndrome,[@R29] here a silent mutation in COL11A1 results in missplicing of the COL11A1 transcript. The silent c.2607A\>G, p.Ala869Ala mutation in family 3 resulted in three different splice isoforms. First it was spliced normally, second the mutation created a de novo donor splice site (as predicted by in silico analysis) and third it also activated a pseudoexon in the preceding intron. Both of the misspliced isoforms resulted in premature termination of the message and were only detected after inhibition of nonsense mediated decay. The effect of this mutation is to reduce the level of expression of the mutant allele, without resulting in a null allele. Unlike in families 1 and 2, where naturally occurring alternative splicing removes the mutation from certain tissues, here it was variation caused by the mutation that modified the phenotype. It is possible that the proportion of the various isoforms may differ from tissue to tissue, depending upon the expression of transacting splicing factors, but this has not been investigated.

C-propeptide mutation {#s4d}
---------------------

Family 3 also had a novel C-propeptide mutation, changing a conserved glycine residue and incorporating an extra cysteine into the C-propeptide. This domain of the fibrillar collagens has a highly conserved pattern of cysteine residues which are important in forming intramolecular and intermolecular disulphide bonds during the trimerisation process of a collagen molecule.[@R38] [@R39] Although mutations in the C-propeptide of other fibrillar collagens have been described, this is the first example of a C-propeptide mutation in α1(XI) collagen. In other collagens, mutations within this domain can produce a wide variety of phenotypes depending upon how they affect its folding and function.[@R32] It is likely that this extra cysteine will disrupt this process, as do similar mutations, that also create additional cysteines in the C-propeptides of α1(I) and α1(II) collagens.[@R40; @R41; @R42] Along with the silent mutation c.2607A\>G, p.Ala869Ala, inherited from the father, they result in Stickler syndrome. Because the silent mutation can also be spliced normally, it is not clear what phenotype would result if this novel C-propeptide mutation had been inherited with a null allele.

In summary, the identification here of a recessive form of type 2 Stickler syndrome, associated with unusually profound hearing loss, highlights the necessity for a detailed examination of both parents and a detailed gene analysis. It should not be assumed that a glycine substitution in the α1(XI) collagen helix is dominant and the sole pathogenic cause of type 2 Stickler syndrome. Of the 77 type 2 Stickler patients, with characterised dominant mutations seen in our clinic, none had profound (ie, greater than 95 dB) hearing loss (unpublished data), which agrees with the recent review by Acke *et al*.[@R18] In this respect, families 1 and 2 were distinctive in their profound hearing loss, which may be an indication that it is associated with a recessive mode of inheritance.
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